MOL 4239

Drug Profile

MOL 4239

Alternative Names: MOL4239; WP 1220

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Dermin; Moleculin; Moleculin Biotech
  • Class Antipsoriatics; Cinnamates; Small molecules
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cutaneous T cell lymphoma
  • Discontinued Plaque psoriasis

Most Recent Events

  • 09 Aug 2018 Moleculin Biotech submits clinical trial authorization application to Polish authorities for Cutaneous T-cell lymphoma
  • 28 Mar 2018 Moleculin Biotech plans a Clinical trial for Cutaneous T-Cell Lymphoma in Poland (Topical)
  • 13 Sep 2017 Moleculin intends to file an IND application for Cutaneous T-Cell Lymphoma in Poland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top